Announcements
Keppra
Several cases of incorrect dose administration have been reported with
Keppra (levetiracetam; UCB Pharma) concentrate for solution for infusion.
The
errors were caused by misinterpretation of the labelling attached to
the vials where the concentration (“100mg/ml”) is in bold
and in larger characters than the total content of the vial (“500mg/5ml
levetiracetam”).
Patients were administered five times the prescribed
dose. Labelling on the vials is being changed to make it more obvious
that each vial of Keppra concentrate for infusion contains 500mg of
levetiracetam.
UCB Pharma is advising pharmacists to keep this in mind
when dispensing
prescriptions for Keppra and to pass on this information to relevant
staff.
Pharmacists who have observed cases of misinterpretation of
the labelling attached to the vials should report any adverse events
to UCB
Pharma on 01753 534655. Further information is also available on
this number. |
The
Pharmaceutical Journal